Larimar Therapeutics Statistics
NASDAQ: LRMRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
2.75-0.03 (-1.08%)
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Larimar Therapeutics by the numbers
Larimar Therapeutics has a market capitalization of $285.7 million based on 103.88M shares outstanding. With trailing EPS of $-1.99, Larimar Therapeutics is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 28.3% below its 50-day average and 29.8% below its 200-day average.
Average daily trading volume is 1.33M shares, or about $3.7 million in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
LRMR valuation vs. peer median
| Metric | LRMR | Peer median | Difference |
|---|---|---|---|
| Market cap | $285.68M | $280.41M | +2% |
| Avg. volume | 1.33M | 1.20M | +11% |
Peer median across 8 companies: BIOA, ABEO, CATX, FULC, RCKT, INDP, BBOT, VNDA.
Valuation
- Market cap
- $285.68M
- EPS (TTM)
- $-1.99
- Shares outstanding
- 103.88M
Price and trading
- Previous close
- 2.78
- Open
- 2.77
- Day range
- 2.72 – 2.84
- 52-week range
- 2.72 – 6.42
- 52-week change
- -41.74%
- Beta
- —
- Volume
- 717.37K
- Average volume
- 1.33M
Dividends and events
- Annual dividend
- None
- Next earnings date
- Nov 4, 2026
Additional statistics
- Market Cap
- 285.68M
- Forward Pe
- -2.59
- Eps
- -1.99
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 6.42
- Week52 Low
- 2.72
- Avg Volume
- 1.33M
- Shares Outstanding
- 103.88M
- Ma50
- 3.83
- Ma200
- 3.92
- Earnings Date
- Nov 4, 2026
- Pct From52w High
- -57.17%
- Pct From52w Low
- 1.29%